| Literature DB >> 22283033 |
Emily H Siegel1, Katarzyna Kordas, Rebecca J Stoltzfus, Joanne Katz, Subarna K Khatry, Steven C LeClerq, James M Tielsch.
Abstract
Despite concerns over the neurocognitive effects of micronutrient deficiencies in infancy, few studies have examined the effects of micronutrient supplementation on specific cognitive indicators. This study investigated, in 2002, the effects of iron-folic acid and/or zinc supplementation on the results of Fagan Test of Infant Intelligence (FTII) and the A-not-B Task of executive functioning among 367 Nepali infants living in Sarlahi district. Infants were enrolled in a cluster-randomized, placebo-controlled clinical trial of daily supplementation with 5 mg of zinc, 6.25 mg of iron with 25 microg of folic acid, or zinc-iron-folic acid, or placebo. These were tested on both the tasks using five indicators of information processing: preference for novelty (FTII), fixation duration (FTII), accelerated performance (> or = 85% correct; A-not-B), deteriorated performance (< 75% correct and > 1 error on repeat-following-correct trails; A-not-B), and the A-not-B error (A-not-B). At 39 and 52 weeks, 247 and 333 infants respectively attempted the cognitive tests; 213 made an attempt to solve both the tests. The likelihood of females completing the A-not-B Task was lower compared to males when cluster randomization was controlled [odds ratio = 0.67; 95% confidence interval 0.46-0.97; p < 0.05]. All of the five cognitive outcomes were modelled in linear and logistic regression. The results were not consistent across either the testing sessions or the information-processing indicators. Neither the combined nor the individual micronutrient supplements improved the performance on the FTII or the A-not-B Task (p > 0.05). These findings suggest that broader interventions (both in terms of scope and duration) are needed for infants who face many biological and social stressors.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22283033 PMCID: PMC3259722 DOI: 10.3329/jhpn.v29i6.9896
Source DB: PubMed Journal: J Health Popul Nutr ISSN: 1606-0997 Impact factor: 2.000
Fig. 1.Eligibility and attrition of participating children
Fig. 2.Timeline of study activities
Characteristics of infants randomized to treatment groups
| Characteristics | 39-week visit | |||
| Zinc | Iron/folic acid | Zinc/iron/folic acid | Placebo | |
| Age (months) at enrollment | 7.1 (2.1) | 7.5 (2.0) | 7.1 (2.3) | 7.1 (2.4) |
| % of females | 57.8 | 40.3 | 34.3 | 50 |
| % of low-caste Hindus | 75.8 | 87.1 | 75.8 | 60.7 |
| % of Muslims | 4.7 | 9.7 | 15.7 | 30.6 |
| % of low SES score, below median | 22.0 | 57.1 | 40.3 | 40.3 |
| % of stunted infants | 14.9 | 10.3 | 15.3 | 26.3 |
| % of wasted infants | 14.9 | 6.7 | 12.9 | 1.8 |
| % of underweight infants | 26.1 | 31.0 | 36.5 | 36.8 |
| Haemoglobin | 110.3 (10.2) | 100.6 (12.0) | 102.2 (14.6) | 102.0 (11.1) |
| % of haemoglobin <105 | 25.5 | 61.7 | 47.7 | 57.5 |
| EP | 81.7 (29.2) | 129.1 (76.4) | 122.8 (85.8) | 108.0 (94.6) |
| % of EP >90 | 29.8 | 66.7 | 55.4 | 45.8 |
| No. of supplements received | 29.4 (28.0) | 26.6 (27.7) | 33.4 (32.7) | 25.6 (29.4) |
| 52-week visit | ||||
| Age (months) at enrollment | 7.9 (2.7) | 9.1 (2.8) | 8.7 (3.0) | 8.4 (3.0) |
| % of females | 57.0 | 39.6 | 44.0 | 52.9 |
| % of low-caste Hindus | 75.3 | 88.4 | 80.0 | 67.1 |
| % of Muslims | 6.3 | 8.3 | 16.0 | 27.6 |
| % of low SES score, below median | 25.7 | 54.7 | 48.5 | 42.4 |
| % of stunted infants | 14.5 | 19.3 | 25.9 | 25.0 |
| % of wasted infants | 21.8 | 11.4 | 10.1 | 12.5 |
| % of underweight infants | 32.1 | 40.4 | 44.0 | 48.7 |
| Haemoglobin | 109.1 (10.5) | 101.1 (9.7) | 102.0 (13.1) | 101.5 (10.3) |
| % of haemoglobin <105 | 32.7 | 65.2 | 53.2 | 56.8 |
| EP | 89.4 (57.0) | 130.3 (74.5) | 129.8 (82.0) | 114.5 (89.2) |
| % of EP >90 | 34.5 | 68.5 | 62.8 | 54.9 |
| No. of supplements received | 67.0 (53.9) | 50.3 (53.5) | 58.9 (60.5) | 54.2 (55.5) |
*p<0.05;
**p<0.01;
***p<0.001;
1Values shown as mean (standard deviation)
2Number of assets; median=4 possessions;
3Length-for-age z-score <-2 standard deviations;
4Weight-for-length z-score <-2 standard deviations;
5Weight-for-age z-score <-2 standard deviations;
6Units given in g/L;
7Units given in µmol/mole heme;
EP=Erythrocyte protoporphyrin;
SES=Socioeconomic status
Descriptive statistics for 39-and 52-week testing periods
| Test | 39-week visit | ||||
| Variable | No. | Mean (SD)/No. (%) | Minimum | Maximum | |
| FTII | Preference for novelty | 244 | 60.05 (6.16) | 38.1 | 74.3 |
| FTII | Fixation duration | 233 | 0.319 (0.229) | -0.2 | 1.1 |
| A-not-B Task | A-not-B error | 202 | 48 (23.8) | ||
| A-not-B Task | Accurate performance | 200 | 74 (37) | ||
| A-not-B Task | Deteriorated performance | 200 | 43 (21.5) | ||
| A-not-B Task | Neither accurate nor deteriorated | 200 | 83 (41.5) | ||
| 52-week visit | |||||
| FTII | Preference for novelty | 325 | 61.0 (6.0) | 40.8 | 78.2 |
| FTII | Fixation duration | 323 | 0.271 (0.18) | -0.14 | 0.95 |
| A-not-B Task | A-not-B error | 264 | 71 (26.9) | ||
| A-not-B Task | Accurate performance | 256 | 111 (43.4) | ||
| A-not-B Task | Deteriorated performance | 256 | 37 (14.5) | ||
| A-not-B Task | Neither accurate nor deteriorated | 256 | 108 (42.2) | ||
Preference for novelty: Raw FTII score. Fixation duration: Time spent attending to the stimuli. A-not-B error: No more than 1 error on repeat-following-correct trial, at least 1 error on a reversal trial and either an error on at least one more reversal trial or an error on the trial immediately following the reversal error. Accurate performance: ≥85% correct. Deteriorated performance: <75% correct;
>1 error on repeat-following-correct trials. Repeat-following-correct: Side of hiding remains same, and the subject was correct on previous trial;
FTII=Fagan Test of Infant Intelligence; SD=Standard deviation
Effect of supplementation on mean FTII scores and A-not-B Task odds ratios at 39 and 52 weeks of age from multivariate models adjusted for cluster randomization
| Test | 39-week visit | ||||
| Outcome | Placebo OR (95% CI) | Zinc OR (95% CI) | Iron-folic acid OR (95% CI) | Zinc-iron-folic acid OR (95% CI) | |
| FTII | Preference for novelty | 60.76 (59.51-60.01) | 58.76 (56.80-60.72) | 60.80 (59.46-62.15) | 60.08 (58.21-61.94) |
| FTII | Fixation duration | 1.40 (1.26-1.56) | 1.39 (1.33-1.46) | 1.30 (1.26-1.35) | 1.41 (1.33-1.49) |
| A-not-B Task | A-not-B error | 1.0 | 0.81 (0.38-1.74) | 0.67 (0.17-2.57) | 1.42 (0.54-3.73) |
| A-not-B Task | Accurate performance | 1.0 | 1.31 (0.52-3.27) | 1.11 (0.48-2.55) | 2.94 (1.47-5.91)6 |
| A-not-B Task | Deteriorated performance | 1.0 | 0.66 (0.29-1.52) | 1.37 (0.52-3.58) | 0.35 (0.15-0.84)6 |
| 52-week visit | |||||
| FTII | Preference for novelty | 62.06 (60.98-63.14) | 61.37 (58.46-64.28) | 61.40 (60.21-62.58) | 60.0 (59.03-60.97)6 |
| FTII | Fixation duration | 1.30 (1.27-1.36) | 1.31 (1.27-1.36) | 1.30 (1.28-1.33) | 1.32 (1.28-1.37)6 |
| A-not-B Task | A-not-B error | 1.0 | 1.47 (0.80-2.69) | 1.38 (0.93-2.04) | 1.84 (1.04-3.26)6 |
| A-not-B Task | Accurate performance | 1.0 | 0.89 (0.50-1.60) | 0.91 (0.50-1.70) | 0.83 (0.50-1.36) |
| A-not-B Task | Deteriorated performance | 1.0 | 1.06 (0.58-1.94) | 0.98 (0.48-1.99) | 0.88 (0.34-2.26) |
1Preference for novelty: Raw FTII score;
2Fixation duration: Time spent attending to the stimuli;
3A-not-B error: No more than 1 error on repeat-following-correct trial—at least 1 error on a reversal trial and either an error on at least one more reversal trial or an error on the trial immediately following the reversal error. Repeat-following-correct: Side of hiding remains same and subject was correct on previous trial;
4Accurate performance: ≥85% correct;
5Deteriorated performance: <75% correct;
>1 error on repeat-following-correct trials;
6p<0.05;
CI=Confidence interval;
FTII=Fagan Test of Infant Intelligence;
OR=Odds ratio
Effect of supplementation on mean FTII scores and A-not-B Task odds ratios at 39-and 52-weeks of age from multivariate models adjusted for cluster randomization-sex-caste-and dose1
| Test | 39-week visit | ||||
| Outcome | Placebo OR (95% CI) | Zinc OR (95% CI) | Iron-folic acid OR (95% CI) | Zinc-iron-folic acid OR (95% CI) | |
| FTII | Preference for novelty | 59.38 (57.52-61.25) | 57.46 (55.47-59.44) | 59.41 (57.65-61.17) | 58.63 (55.79-61.47) |
| FTII | Fixation duration | 1.42 (1.29-1.57) | 1.40 (1.35-1.53) | 1.32 (1.25-1.38) | 1.46 (1.36-1.57) |
| A-not-B Task | A-not-B error | 1.0 | 0.33 (0.20-0.56) | 0.31 (0.09-1.06) | 0.70 (0.34-1.41) |
| A-not-B Task | Accurate performance | 1.0 | 0.18 (0.06-0.56) | 0.17 (0.07-0.41) | 0.38 (0.20-0.71) |
| A-not-B Task | Deteriorated performance | 1.0 | 0.41 (0.23-0.75) | 0.95 (0.38-2.38) | 0.24 (0.11-0.56) |
| 52-week visit | |||||
| FTII | Preference for novelty | 62.10 (60.86-63.35) | 61.41 (58.02-64.79) | 61.48 (60.04-62.91) | 60.10 (58.84-61.36) |
| FTII | Fixation duration | 1.30 (1.26-1.34) | 1.33 (1.27-1.39) | 1.30 (1.27-1.34) | 1.33 (1.28-1.39) |
| A-not-B Task | A-not-B error | 1.0 | 0.30 (0.13-0.70) | 0.40 (0.25-0.64) | 0.48 (0.28-0.83) |
| A-not-B Task | Accurate performance | 1.0 | 0.59 (0.29-1.19) | 0.48 (0.21-1.09) | 0.37 (0.22-0.62) |
| A-not-B Task | Deteriorated performance | 1.0 | 0.16 (0.78-0.34) | 0.16 (0.07-0.40) | 0.14 (0.05-0.43) |
1A-not-B Task outcomes were additionally adjusted for A-not-B flag and maximum delay. Dose and maximum delay were centred around their respective means;
2Preference for novelty: Raw FTII score;
3Fixation duration: Time spent attending to the stimuli;
4A-not-B error: No more than 1 error on repeat-following-correct trial—at least 1 error on a reversal trial and either an error on at least one more reversal trial or an error on the trial immediately following the reversal error. Repeat-following-correct: Side of hiding remains same, and subject was correct on previous trial;
5Accurate performance: ≥85% correct;
6Deteriorated performance: <75% correct; >1 error on repeat-following-correct trials;
7p<0.05;
CI=Confidence interval;
FTII=Fagan Test of Infant Intelligence;
OR=Odds ratio